WallStSmart

Kiora Pharmaceuticals Inc (KPRX)vsRegeneron Pharmaceuticals Inc (REGN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Regeneron Pharmaceuticals Inc generates 1689520% more annual revenue ($16.90B vs $1.00M). REGN leads profitability with a 28.5% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 80/100 (B+).

KPRX

Avoid

30

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -8.46

REGN

Strong Buy

80

out of 100

Grade: B+

Growth: 8.7Profit: 8.0Value: 7.3Quality: 8.5
Piotroski: 2/9Altman Z: 4.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KPRX.

REGNUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$1497.56

Current Price

$920.69

$576.87 discount

UndervaluedFair: $1497.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KPRX2 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

REGN6 strengths · Avg: 9.7/10
Operating MarginProfitability
30.4%10/10

Strong operational efficiency at 30.4%

Revenue GrowthGrowth
36.3%10/10

Revenue surging 36.3% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4410/10

Safe zone — low bankruptcy risk

Market CapQuality
$98.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.5%9/10

Keeps 29 of every $100 in revenue as profit

Areas to Watch

KPRX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.12M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

REGN1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : KPRX

The strongest argument for KPRX centers on Price/Book, Debt/Equity.

Bull Case : REGN

The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.

Bear Case : KPRX

The primary concerns for KPRX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : REGN

The primary concerns for REGN are Piotroski F-Score.

Key Dynamics to Monitor

KPRX profiles as a value stock while REGN is a growth play — different risk/reward profiles.

REGN carries more volatility with a beta of 0.10 — expect wider price swings.

REGN is growing revenue faster at 36.3% — sustainability is the question.

REGN generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

REGN scores higher overall (80/100 vs 30/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kiora Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs, underpinned by its expertise in drug formulation and delivery. With a strong commitment to enhancing patient outcomes and a solid research framework, Kiora's strategic partnerships and clinical advancements underscore its potential within the biopharmaceutical sector, offering an attractive investment prospect for institutional investors looking to capitalize on the next generation of therapeutics.

Visit Website →

Regeneron Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Want to dig deeper into these stocks?